He is currently Managing Partner of Turret Capital Management, a global investment firm that incubates and invests in healthcare companies. He served as Portfolio Manager at several leading firms where he led healthcare investments teams, including Citadel Investment Group, UBS (Proprietary Trading Group), and Neuberger Berman. He has both early stage investment and strategic experience having served on the board of Nexgen Spine, which was acquired by Stryker Corporation.
He holds a B.S. from University of Michigan and received his M.D. from Columbia University, College of Physicians & Surgeons.
Dr. Zhang has successfully managed several high-profile China entry projects across the diagnostic space, including the following:
• Foundation Medicine (technology: personalized tumor diagnosis)
• Ariosa Diagnostics (cell-free DNA system)
• Otogenetics Corporation (next-generation sequencing)
• Biocore Co (genetic diagnosis)
• Metabolon, Inc. (metabolomics)
• Johns Hopkins Hospital (university’s full-suite of diagnostic services)
He was also co-founder and former CTO of Shanghai ImmunoTech Bioscience. Dr. Zhang served as Lab Manager and Senior Researcher at Dartmouth College where he focused on immunology. He holds an M.D. from Shanghai Jiaotong University School of Medicine, an M.Sc. from Rivier University, and executive education at Dartmouth College’s Tuck School of Business
He served as the General Manager of Healthcare Products at WIPAK Group, a global conglomerate based in Finland, in which he was fully responsible for product import, planning, logistics, license approval, marketing, sales networks, and management.
Previously, he was the Area Sales Manager of Shanghai Worldeast Commercial & Industrial Co; there, he fulfilled his role as the Sole Agent of Abbott Murex Diagnostic Products in China. Accordingly, he was responsible for channel management and sales of all Abbott Murex’s diagnostic products, including the automatic immunological analysis systems of DYNEX and Genesis; he was also managing the sales processes of other instruments such as the Fresenius blood transfusion system and the Abbott Determine rapid diagnostic products for CDC and CIQ.
Dr. Bao earned his M.D. from Shanghai JiaoTong University School of Medicine.
Before that, Mark served as Business Development Manager and Investor Relations Manager at Hao Tian Development Group Limited, a Hong Kong-listed company (0474.HK). He focused on growing opportunities in China and contributed to investment, financing and operation in mineral, energy, healthcare and agricultural industries.
Mark holds a BCom in Finance from the Haskyne School of Business, University of Calgary, an M.S. in International Banking and Finance from Ling Nan University, and an Executive Diploma in Merger and Acquisition from HKU SPACE.
Before joining Milu Labs, she had spent close to 30 years occupying leadership positions in Mcdonald’s China. Zhang pioneered the establishment of the first Ronald McDonald House in China, leading the Ronald McDonald House Charity project across the country. As a core aspect of this initiative, she coordinated with top-tier children’s hospitals and provided accommodation services for families in need; for example, she led the establishment of the Shanghai Ronald McDonald House and cooperated with the Shanghai Children Medicine Center in 2020. In addition, she directed McDonald’s Public Relations and Corporate Affairs departments in Beijing and China’s northern region from 1996 to 2014.
Ms. Zhang has a M.S. in Oral Medicine and a B.S. in Stomatology from Capital Medical University.
Scientific Advisory Board
Dr. Chan has won several awards including the Morton K. Schwartz Award for Cancer Research Diagnostics, Albert Nichols Award for strategic innovation in laboratory medicine, and Bernard Gerulat Award for outstanding achievement in clinical chemistry .B.A. from the University of Oregon; Ph.D. from the State University of New York at Buffalo
He has worked with Dr. Chan to produce the first in vitro diagnostic multivariate index assay (IVDMIA) of proteomic biomarkers ever cleared by FDA for clinical use. He has also published more than 130 articles focusing primarily on biomarker analysis and bioinformatics.
Current board appointments include Sword Diagnostics, Inc., NxPrenatal, Inc., and Chembio (NASDAQ: CEMI). Appointed as the Chief Business Advisor for the Dell Medical School Catalyst/UT Board. B.S. from the University of Florida; executive education at the Northwestern University Kellogg School of Management